Overath, Germany

Teunis Schuurmann


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Teunis Schuurmann: Innovator in the Field of Central Nervous System Agents

Introduction

Teunis Schuurmann, a dedicated inventor based in Overath, Germany, has made significant contributions to the field of medicinal chemistry. With a focus on the development of compounds that affect the central nervous system, he has garnered attention in both academic and commercial circles.

Latest Patents

Among his notable achievements is a patent involving 2-pyrimidinyl-1-piperazine derivatives. This invention details substituted 2-pyrimidinyl-1-piperazine derivatives defined by a specific formula, processes for their manufacture, and compositions that incorporate these derivatives as active materials. Furthermore, the patent emphasizes the use of these compounds as agents impacting the central nervous system, making it a pivotal development in therapeutic applications. The invention also includes intermediates vital for synthesizing the active compounds.

Career Highlights

Teunis Schuurmann is currently employed at Troponwerke GmbH & Co. KG, a company renowned for its innovation in chemical products. His work at Troponwerke reflects a commitment to advancing pharmacological solutions that can benefit areas such as neurology and psychiatry.

Collaborations

Throughout his career, Schuurmann has worked alongside reputable colleagues, including Peter-Rudolf Seidel and Harald Horstmann. These collaborations have likely enriched his research and development endeavors, contributing to the overall progress in the field of medicinal compounds.

Conclusion

Teunis Schuurmann stands out as an inventor whose work on 2-pyrimidinyl-1-piperazine derivatives demonstrates the impactful intersection of chemistry and medicine. His dedication to innovation is evidenced by his patent and his collaborations with fellow professionals in the industry, promising advancements that could enhance treatment options for central nervous system-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…